Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
Public ClinicalTrials.gov record NCT00600886. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly
Study identification
- NCT ID
- NCT00600886
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 358 participants
Conditions and interventions
Conditions
Interventions
- Pasireotide Drug
- Octreotide Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 10, 2008
- Primary completion
- Mar 10, 2016
- Completion
- Mar 10, 2016
- Last update posted
- Jul 1, 2017
2008 – 2016
United States locations
- U.S. sites
- 14
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cedars Sinai Medical Center The Pituitary Center | Los Angeles | California | 90048 | — |
| University of California at Los Angeles Division of Endocrinology | Los Angeles | California | 90095 | — |
| Stanford University Medical Center Stanford Cancer Center (3) | Stanford | California | 94304 | — |
| University of Florida SC | Gainesville | Florida | 32610 | — |
| Johns Hopkins University School of Medicine Dept.ofJohnsHopkinsUniv. | Baltimore | Maryland | 21205 | — |
| University of Michigan Comprehensive Cancer Center Deptof Endocrinology&Diabetes | Ann Arbor | Michigan | 48109-0944 | — |
| Columbia University Medical Center- New York Presbyterian Dept. of CU Collegeof Phys&Sur | New York | New York | 10032 | — |
| Northport VA Medical Center CSOM230C2305 | Northport | New York | 11768 | — |
| Oregon Health & Sciences University DeptofOregonHealth&Sciences(3) | Portland | Oregon | 97201 | — |
| Allegheny Endocrinology Associates | Pittsburgh | Pennsylvania | 15212 | — |
| University of Texas Southwestern Medical Center Danziger Research Bldg. | Dallas | Texas | 75390 | — |
| University of Texas/MD Anderson Cancer Center Regulatory -12 | Houston | Texas | 77030-4009 | — |
| Baylor College of Medicine | Houston | Texas | 77030 | — |
| Swedish Medical Center Dept.ofSeattle Neuroscience(2) | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 81 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00600886, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 1, 2017 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00600886 live on ClinicalTrials.gov.